CN107428809B - 一种重组蛋白质药物的分子设计 - Google Patents

一种重组蛋白质药物的分子设计 Download PDF

Info

Publication number
CN107428809B
CN107428809B CN201680010044.XA CN201680010044A CN107428809B CN 107428809 B CN107428809 B CN 107428809B CN 201680010044 A CN201680010044 A CN 201680010044A CN 107428809 B CN107428809 B CN 107428809B
Authority
CN
China
Prior art keywords
seq
motif
mutant
activity
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680010044.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107428809A (zh
Inventor
罗永章
刘鹏
鲁薪安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Priority to CN202111201002.3A priority Critical patent/CN114249816B/zh
Publication of CN107428809A publication Critical patent/CN107428809A/zh
Application granted granted Critical
Publication of CN107428809B publication Critical patent/CN107428809B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201680010044.XA 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计 Active CN107428809B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111201002.3A CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510079486 2015-02-13
CN2015100794867 2015-02-13
CN201510736184 2015-11-02
CN2015107361842 2015-11-02
PCT/CN2016/073773 WO2016127948A1 (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111201002.3A Division CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Publications (2)

Publication Number Publication Date
CN107428809A CN107428809A (zh) 2017-12-01
CN107428809B true CN107428809B (zh) 2021-10-01

Family

ID=56614147

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680010044.XA Active CN107428809B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计
CN202111201002.3A Active CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111201002.3A Active CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Country Status (7)

Country Link
US (2) US10869910B2 (https=)
EP (1) EP3269731B1 (https=)
JP (1) JP6896636B2 (https=)
CN (2) CN107428809B (https=)
AU (2) AU2016218635B2 (https=)
DK (1) DK3269731T5 (https=)
WO (1) WO2016127948A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180015148A1 (en) * 2014-11-03 2018-01-18 Tsinghua University Drug for inhibiting adipose cell differentiation and insulin resistance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization;Yujing Bai等;《PLoS One》;20141107;第9卷(第11期);全文 *
Effects of the C-terminal of endostatin on the tumorigenic potential of H22 cells;Xia Qi等;《Biomed Rep.》;20130722;第1卷(第5期);全文 *
Improved biological activity of a mutant endostatin containing a single amino-acid substitution;Y Yokoyama等;《British Journal of Cancer》;20040419;第90卷(第8期);全文 *
内皮抑素基因定点突变体的构建;殷秀丽等;《国际眼科杂志》;20090415;第9卷(第2期);全文 *

Also Published As

Publication number Publication date
EP3269731A4 (en) 2018-08-15
CN114249816A (zh) 2022-03-29
CN107428809A (zh) 2017-12-01
US10869910B2 (en) 2020-12-22
AU2020256316B2 (en) 2021-10-07
US20180200337A1 (en) 2018-07-19
JP6896636B2 (ja) 2021-06-30
WO2016127948A1 (zh) 2016-08-18
EP3269731B1 (en) 2023-10-04
CA3014538A1 (en) 2016-08-18
US20210085754A1 (en) 2021-03-25
CN114249816B (zh) 2024-09-06
AU2016218635B2 (en) 2020-07-23
AU2020256316A1 (en) 2020-11-12
DK3269731T5 (da) 2024-10-14
DK3269731T3 (da) 2023-10-30
AU2016218635A1 (en) 2017-10-05
EP3269731A1 (en) 2018-01-17
JP2018507854A (ja) 2018-03-22

Similar Documents

Publication Publication Date Title
US20180163214A1 (en) Slit2d2-hsa fusion protein and use thereof against tumours
AU2006257286B2 (en) Uses of recombinant super-compound interferons
CN107428809B (zh) 一种重组蛋白质药物的分子设计
CN106432483B (zh) 沼水蛙皮肤丝氨酸蛋白酶抑制肽及其基因和制药应用
US20220033439A1 (en) Peptide targeting mycobacterium tuberculosis toxin-antitoxin system and use thereof
CN114796525A (zh) 细胞周期调控蛋白抑制剂在肿瘤治疗中的应用
CA3014538C (en) Molecular design of recombinant protein drug
CN117899223A (zh) 以nup35基因和或以nup35蛋白作为作用靶点的物质的应用及组合物
CN103755813A (zh) 一种靶向性抗肿瘤融合蛋白及其编码基因与表达质粒
HK1240943B (zh) 一种重组蛋白质药物的分子设计
HK1240943A1 (en) Molecular design of recombinant protein drug
CN100398557C (zh) 血管生成抑制多肽及其制备方法和应用
WO2004091650A1 (fr) Utilisation de la troponine i cardiaque pour preparer des medicaments antitumoraux
WO2020061389A1 (en) Engineered microorganisms and methods of making and using same
CN101356190A (zh) 用于抑制pf4和rantes相互作用的拮抗剂
TWI328011B (en) Recombinant super-compound interferon
JP2006504403A5 (https=)
CN118184758A (zh) 用于抑制端粒酶活性的多肽及其癌症治疗中的应用
CN101144081A (zh) 核苷酸分子trail及其在制备治疗肿瘤药物中的应用
KR20210155229A (ko) Hoxa9 단백질 c-말단부위의 hadp 펩티드를 포함하는 폐암의 예방, 개선 또는 치료용 약학적 조성물
JPS6150923A (ja) ヒト癌壊死因子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240943

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant